5 key milestones in FDA-approved digital therapeutics

FDA approved 50% more Digital Therapeutics (DTx) in 2023 compared to 2022.

Nerivio is a wearable device for migraine treatment, utilizing remote electrical neuromodulation.

Lenire received FDA De Novo approval as a pioneering tinnitus treatment device.

Somryst is the first FDA-approved DTx for chronic insomnia.

ReSET and ReSET-O are FDA-cleared DTx for substance use disorders.